ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Merck & Co. will pay Chimerix $17.5 million up front for access to CMX157, a nucleoside reverse transcriptase inhibitor for the treatment of HIV. Chimerix could receive an additional $151 million in milestone payments as CMX157, which has completed Phase I studies, moves toward the market. CMX157 is a lipid conjugate of the already-approved HIV treatment tenofovir, marketed by Gilead Sciences as Viread. Research Triangle Park, N.C.-based Chimerix says proceeds will be used to support the development of CMX001, which is expected to move into Phase III studies as a cytomegalovirus treatment in early 2013.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X